Hikma Ventures

Founded in 2012, Biolinq develops digital health platforms centered around skin-applied electronic biosensors. These minimally invasive sensors analyze biomarkers in interstitial fluid to provide real-time, actionable health information, initially focusing on continuous glucose monitoring for diabetic patients.

Octave is a clinical platform developer focused on transforming the care landscape for multiple sclerosis and other neurodegenerative diseases. The company creates a platform that generates, analyzes, and integrates data to improve patient outcomes and reduce overall healthcare costs. By optimizing medication usage and healthcare services, Octave aims to enhance the efficiency of the pharmaceutical industry throughout the entire lifecycle of drug development, which includes discovery, clinical trials, and post-marketing phases. Their approach utilizes real-world evidence to inform decision-making, ultimately striving to set a new standard in multiple sclerosis care.

Prognos Health is a healthcare technology company specializing in advanced analytics. Its platform, prognosFACTOR, enables querying of billions of de-identified patient records for clinically-focused insights within minutes. The platform facilitates the purchase and use of HIPAA-compliant data for applications such as cohort design, patient journey studies, and health outcomes analysis. Prognos Health serves 25 of the top 30 pharmaceutical manufacturers and three of the top five payers.

O7 Therapy offers a digital platform and mobile app for Arabic-speaking users to access online therapy sessions with licensed professionals. It provides psycho-educational resources, corporate wellness programs, and employee wellness initiatives through a B2B2E model.

Altoida AG, founded in 2016 and headquartered in Lucerne, Switzerland, specializes in developing innovative healthcare solutions for Alzheimer's patients. The company has created a platform that transforms the assessment of brain function and the diagnosis of neurological diseases through the use of smartphones and tablets. Their flagship product, a Computerized Cognitive Assessment Aid, has received FDA Breakthrough Device Designation, reflecting its potential to significantly improve patient outcomes. Altoida's approach is grounded in over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence, employing machine-learning algorithms to evaluate cognitive and functional performance. The platform aims to enable healthcare professionals to detect Alzheimer's and dementia at an early stage, providing critical insights that can inform treatment strategies.

Altibbi Ltd. is a digital health platform based in Dubai, United Arab Emirates, that connects users with healthcare information and services throughout the Middle East. Founded in 2008, Altibbi offers a comprehensive range of resources, including medical articles, videos, a medical dictionary, and an encyclopedia of medicines. The platform addresses various health topics, such as chronic diseases, allergies, and dental issues, providing users with the knowledge they need to make informed health decisions. In addition to informational resources, Altibbi facilitates access to healthcare by allowing users to book appointments with qualified doctors via video calls and translating medical terminology into Arabic. The platform is accessible 24/7 through its website and mobile applications, enhancing healthcare access and quality for users in the region.

Activ Surgical is a Boston-based digital surgery company developing a surgical imaging and software platform that uses computer vision, artificial intelligence, analytics, and machine learning to assist surgeons in complex procedures, enhance intraoperative decision-making, improve efficiency and accuracy, and reduce unintended complications. The platform supports augmented reality-based guidance and AI-driven surgery, and its robotic initiatives include the Smart Tissue Autonomous Robot, a system designed to automate aspects of tissue manipulation during surgery.

NuvoAir is a healthcare technology company that offers a value-based specialty care platform and remote monitoring tools for chronic heart and lung conditions. Founded in 2015 and based in Stockholm, Sweden, it develops home respiratory monitoring and analytics delivered by a multidisciplinary team of pulmonologists and cardiologists. The platform enables proactive virtual care and partners with health plans and risk-bearing entities under flexible, value-based payment arrangements to improve patient outcomes and reduce healthcare costs by enabling early detection of deterioration and personalized management.

BioSapien is a biotechnology company developing innovative, biodegradable implantable devices that deliver pharmaceuticals directly to cancer sites. Its flagship product, MediChip, uses 3D printing technology to create a mesh capable of sustained drug release, reducing systemic side effects and improving patient care.

Founded in 2012, Biolinq develops digital health platforms centered around skin-applied electronic biosensors. These minimally invasive sensors analyze biomarkers in interstitial fluid to provide real-time, actionable health information, initially focusing on continuous glucose monitoring for diabetic patients.

Click Therapeutics is a New York‑based company that develops and commercializes digital therapeutics that use cognitive and neurobehavioral techniques to treat a range of medical conditions. Its platform personalizes treatment through an adaptive data science engine, aiming to improve engagement and clinical outcomes. The company’s flagship smoking‑cessation program has been approved for nationwide use and is available through payers, providers, and employers. It is also conducting a phase III FDA‑registered trial for a prescription digital therapy for major depressive disorder. Other indications under development include schizophrenia, insomnia, acute coronary syndrome, migraine, overactive bladder, chronic low back pain, and obesity. Founded in 2012, Click Therapeutics focuses on delivering software as a medical treatment that can be used independently or alongside conventional therapies.

SeamlessMD is a developer of a digital patient engagement platform focused on improving health outcomes for patients undergoing surgery. The company addresses the challenges of traditional surgical care, which often relies on paper instructions and human memory, by utilizing design, data, and technology to enhance the patient experience. SeamlessMD's platform supports hospitals in engaging patients through remote monitoring and data collection, which helps optimize recovery processes and reduce readmission rates. By collaborating with healthcare providers, SeamlessMD aims to deliver high-quality surgical care while lowering costs, ultimately ensuring patients have a better and more informed journey through their surgical experiences.

Founded in 2013, Lemonaid Health specializes in improving patient experience through advanced machine learning and AI. It offers direct-to-consumer telemedicine services, utilizing evidence-based guidelines to provide affordable healthcare.

Altoida AG, founded in 2016 and headquartered in Lucerne, Switzerland, specializes in developing innovative healthcare solutions for Alzheimer's patients. The company has created a platform that transforms the assessment of brain function and the diagnosis of neurological diseases through the use of smartphones and tablets. Their flagship product, a Computerized Cognitive Assessment Aid, has received FDA Breakthrough Device Designation, reflecting its potential to significantly improve patient outcomes. Altoida's approach is grounded in over 20 years of research in digital biomarkers, augmented reality, and artificial intelligence, employing machine-learning algorithms to evaluate cognitive and functional performance. The platform aims to enable healthcare professionals to detect Alzheimer's and dementia at an early stage, providing critical insights that can inform treatment strategies.

WinterLight Labs Inc. is a Toronto-based company founded in 2015 that specializes in developing a speech-based platform for the detection and monitoring of cognitive and mental diseases, including dementia and Alzheimer's disease. The company's innovative AI technology analyzes natural speech samples to quantify various speech and language patterns, enabling the accurate assessment of cognitive health. By utilizing a brief one-minute speech sample, WinterLight's platform can characterize aspects such as lexical diversity, syntactic complexity, semantic content, and articulation, effectively capturing the speaker's cognitive state. This diagnostic tool has significant applications across clinical trials, long-term care, primary care, and speech-language pathology, facilitating the early detection of cognitive impairment and tracking disease progression.

Pillo Health is a company focused on enhancing the quality of life for patients managing their health at home through its innovative care delivery platform. Central to this platform is Pillo, an intelligent healthcare assistant designed to assist caregivers and health organizations in delivering improved care. Pillo manages medication schedules, provides personalized health and wellness information, and proactively delivers digital care plans to patients. Additionally, it facilitates communication between patients and care teams through smart notifications and video calling. Pillo Health also offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further expanding its capabilities in home healthcare management.

Founded in 2012, Biolinq develops digital health platforms centered around skin-applied electronic biosensors. These minimally invasive sensors analyze biomarkers in interstitial fluid to provide real-time, actionable health information, initially focusing on continuous glucose monitoring for diabetic patients.

Nebula Genomics is a biotechnology company founded in 2016 and based in San Francisco, California. It specializes in human genome sequencing and the creation of a marketplace for genomic and health data aimed at consumers, researchers, and the medical community. The company's mission is to facilitate genomic sequencing and enhance personalized medicine by aggregating a substantial repository of genetic information. Utilizing blockchain technology, Nebula Genomics ensures that consumers retain control over their data and receive compensation for its use. The marketplace enables researchers to analyze rich genetic datasets, which can accelerate drug development and improve the efficiency of clinical trials. Founded by prominent genomics researcher George Church and his associates, Nebula Genomics offers advanced DNA sequencing technology that allows clients to explore all genes and genetic variants in the genome, thereby providing comprehensive insights into individual health.

Click Therapeutics is a New York‑based company that develops and commercializes digital therapeutics that use cognitive and neurobehavioral techniques to treat a range of medical conditions. Its platform personalizes treatment through an adaptive data science engine, aiming to improve engagement and clinical outcomes. The company’s flagship smoking‑cessation program has been approved for nationwide use and is available through payers, providers, and employers. It is also conducting a phase III FDA‑registered trial for a prescription digital therapy for major depressive disorder. Other indications under development include schizophrenia, insomnia, acute coronary syndrome, migraine, overactive bladder, chronic low back pain, and obesity. Founded in 2012, Click Therapeutics focuses on delivering software as a medical treatment that can be used independently or alongside conventional therapies.

Propeller Health is a digital health company specializing in respiratory disease management. Its platform comprises sensors that attach to inhalers, syncing wirelessly with smartphones via a mobile app. The platform tracks medication usage and triggers symptoms, providing personalized feedback and reminders. It also facilitates data sharing with healthcare providers and family members.

Founded in 2012, Biolinq develops digital health platforms centered around skin-applied electronic biosensors. These minimally invasive sensors analyze biomarkers in interstitial fluid to provide real-time, actionable health information, initially focusing on continuous glucose monitoring for diabetic patients.

Prognos Health is a healthcare technology company specializing in advanced analytics. Its platform, prognosFACTOR, enables querying of billions of de-identified patient records for clinically-focused insights within minutes. The platform facilitates the purchase and use of HIPAA-compliant data for applications such as cohort design, patient journey studies, and health outcomes analysis. Prognos Health serves 25 of the top 30 pharmaceutical manufacturers and three of the top five payers.

Founded in 2013, Lemonaid Health specializes in improving patient experience through advanced machine learning and AI. It offers direct-to-consumer telemedicine services, utilizing evidence-based guidelines to provide affordable healthcare.

Pillo Health is a company focused on enhancing the quality of life for patients managing their health at home through its innovative care delivery platform. Central to this platform is Pillo, an intelligent healthcare assistant designed to assist caregivers and health organizations in delivering improved care. Pillo manages medication schedules, provides personalized health and wellness information, and proactively delivers digital care plans to patients. Additionally, it facilitates communication between patients and care teams through smart notifications and video calling. Pillo Health also offers a software development kit (SDK) that allows partner organizations to create customized skills for the Pillo device, further expanding its capabilities in home healthcare management.

Propeller Health is a digital health company specializing in respiratory disease management. Its platform comprises sensors that attach to inhalers, syncing wirelessly with smartphones via a mobile app. The platform tracks medication usage and triggers symptoms, providing personalized feedback and reminders. It also facilitates data sharing with healthcare providers and family members.

Chrono Therapeutics Inc. is a pharmaceutical company based in Hayward, California, focused on revolutionizing drug delivery and addiction management. Founded in 2003, the company specializes in the development of SmartStop, a digital nicotine replacement therapy that employs a wearable device to deliver programmable, transdermal drug therapy. This innovative system is designed to tailor the timing and dosage of nicotine while providing real-time behavioral support to help users manage addiction and smoking cessation effectively. Chrono Therapeutics aims to address the challenges associated with smoking addiction through its advanced technology, which seeks to achieve optimal clinical outcomes and improve the overall quality of life for users. The company's leadership team brings extensive experience in product development, research and development, and navigating regulatory pathways, positioning Chrono Therapeutics as a key player in the smoking cessation market.